gemcitabine has been researched along with lenvatinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cheng, J; Feldman, R; Fuks, Z; Fuller, J; Kolesnick, R; Owa, T; Tap, W | 1 |
| Chen, X; Li, Y; Qian, Y; Qiao, L; Shi, C; Tang, L; Wu, D; Xie, F; Yang, C; Yang, J; Zheng, Y | 1 |
| Chen, XP; Luo, C; Zhang, BX; Zhang, W; Zhang, ZY | 1 |
1 review(s) available for gemcitabine and lenvatinib
| Article | Year |
|---|---|
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged | 2022 |
3 other study(ies) available for gemcitabine and lenvatinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Deoxycytidine; Endothelial Cells; Gemcitabine; Male; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sarcoma; Soft Tissue Neoplasms; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Quinolines; Retrospective Studies | 2022 |